Anthem Biosciences Delivers Strong FY26 Financial Performance

Key Financial Highlights for FY26 and Q4 FY26

Anthem Biosciences has announced its audited consolidated financial results for the fiscal year and fourth quarter ending March 31, 2026. The company achieved a 15.2% year-over-year increase in consolidated revenue for the full fiscal year, reaching ₹21,243 million. During the same period, Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) grew by 30.8% to ₹9,896 million, and Profit After Tax (PAT) surged by 31.1% to ₹5,918 million.

The fourth quarter of FY26 demonstrated even more impressive performance. Consolidated revenue saw a 26.4% year-over-year increase, totaling ₹6,109 million. EBITDA in Q4 FY26 jumped 52.2% to ₹3,184 million, and PAT experienced a remarkable surge of 129.8% to ₹1,898 million.

Business Growth and Profitability Insights

These robust financial figures reflect significant business growth and improved profitability for Anthem Biosciences. The substantial rise in PAT, particularly in the fourth quarter, highlights effective operational efficiency and cost management strategies. As of March 31, 2026, the company maintained a strong net cash position of ₹13,743 million.

Strategic Focus on Global CRDMO Platform

Anthem Biosciences has been actively developing an agile, science-led, and future-ready Contract Research, Development, and Manufacturing Organization (CRDMO) platform. This strategic direction appears to be a key driver of its strong financial performance, culminating in the achievement of its highest revenue quarter ever in Q4 FY26.

Future Outlook and Investor Confidence

Management at Anthem Biosciences expresses optimism regarding the company's future trajectory, with a goal to solidify its position as a premier global CRDMO. The strong performance recorded in FY26 is anticipated to boost investor confidence and provide support for the company's strategic expansion initiatives.

Market Competition and Growth Sustainability

While the recent results are highly positive, Anthem Biosciences operates within a competitive global CRDMO landscape. The company's ability to sustain its high growth rates and profitability amidst evolving market conditions will be a key factor to monitor.

Key Metrics

• Full Year FY26 Revenue: ₹21,243 Mn (up 15.2% YoY)
• Full Year FY26 PAT: ₹5,918 Mn (up 31.1% YoY)
• Q4 FY26 Revenue: ₹6,109 Mn (up 26.4% YoY)
• Q4 FY26 PAT: ₹1,898 Mn (up 129.8% YoY)
• Net Cash: ₹13,743 Mn as of March 31, 2026

Next Steps for Investors

Investors will be keen to gather further insights into the company's performance drivers and future outlook during the upcoming earnings call scheduled for May 20, 2026.